市場調查報告書

Trastuzumab:生物相似藥的洞察(2020年)

Trastuzumab - Biosimilars Insight, 2020

出版商 DelveInsight Business Research LLP 商品編碼 955876
出版日期 內容資訊 英文 125 Pages
商品交期: 最快1-2個工作天內
價格
Trastuzumab:生物相似藥的洞察(2020年) Trastuzumab - Biosimilars Insight, 2020
出版日期: 2020年08月01日內容資訊: 英文 125 Pages
簡介

以Herceptin這個品牌名販售Trastuzumab,是乳癌和胃癌的治療使用的單株抗體,特別使用於HER2受體陽性的癌症。可單獨或與其他的化療藥一起使用。企業和研究人員,評估課題,摸索著給予Trastuzumab的研究開發的影響的可能性的機會,以治療/改善Trastuzumab的新方法為焦點。

本報告提供Trastuzumab的相關調查,藥物概要,生物相似藥的法規預測,研究開發,機會,主要企業的簡介等資訊。

目錄

第1章 主要洞察

第2章 概述

第3章 摘要整理

第4章 生物相似藥的法規預測

  • 北美
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
  • 其他地區
    • 巴西
    • 墨西哥
    • 阿根廷
    • 沙烏地阿拉伯

第5章 Trastuzumab(參照產品:Herceptin)

  • 藥物簡介
  • 產品概要
  • 法規核准與發售
  • 適應症
  • 作用機制
  • 投藥和管理
  • 劑量和優勢
  • 輻射劑量變更
  • 合成的路徑
  • 藥理學
  • 藥效學
  • 藥物動力學
  • 有害反應
  • 產品的概述
  • 開發里程碑

第6章 研究開發

  • 臨床試驗資訊
  • 安全性和有效性

第7章 Herceptin生物相似藥:新機會

第8章 生物相似藥的評估

  • 各產品類型評估
  • 各給藥途徑評估
  • 各分子類型評估
  • 銷售核定

第9章 企業簡介

    • Amgen
    • EirGenix
    • Celltrion
    • Prestige BioPharma

第10章 比較形勢:各企業

第11章 競爭情形

    • 概況
    • 市場佔有率分析
    • 競爭模式

第12章 市場成長要素

第13章 市場障礙

第14章 SWOT分析

第15章 附錄

第16章 參考文件

第17章 DelveInsight的服務內容

第18章 免責聲明

第19章 關於DelveInsight

目錄
Product Code: DIBI000004

DelveInsight's , "Trastuzumab- Biosimilar Insight, 2020," report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Trastuzumab Understanding

Trastuzumab: Overview

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture which may contain the antibiotic gentamicin. Gentamicin is not detectable in the final product. Herceptin (trastuzumab) for injection is a sterile, white to pale yellow, preservative-free lyophilized powder with a cake-like appearance, for intravenous administration.

Trastuzumab Biosimilars: Drugs Chapters

This segment of the Trastuzumab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Trastuzumab Biosimilars: Marketed Drugs

  • Kanjinti: Amgen

Kanjinti is a biosimilar to trastuzumab, a recombinant DNA-derived humanized monoclonal immunoglobulin G1 kappa antibody. The active ingredient of KANJINTI is a humanized monoclonal antibody that has the same amino acid sequence, structure and function as trastuzumab. Kanjinti has the same pharmaceutical dosage form and same strength after reconstitution as trastuzumab.

  • Herzuma: Celltrion

Herzuma is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer. Herzuma is the second FDA-approved trastuzumab biosimilar, following Mylan and Biocon's approval for Ogivri in December 2017 (Ogivri has not yet launched in the United States). Herzuma has also earned approval in the European Union (where it is marketed by Mundipharma), in Japan (where it is marketed by Daiichi Sankyo), and in Australia.

Further product details are provided in the report.

Trastuzumab Biosimilars: Emerging Drugs

  • EG12014: EirGenix

EG12014 is a biosimilar of trastuzumab, which is Roche's monoclonal antibody with brand name called Herceptin. A biosimilar drug is a near-identical copy of an original biologics and a different company can manufacture it after the expiration of the original biologics' patent. Eirgenix has begun preparations for a phase III clinical trial which would be conducted in the US and European nations. The outcome paves the way for new opportunities for lower-priced biosimilar drugs as patents on mainstream oncology drugs approach their expiration dates in the next few years.

  • HD201: Prestige BioPharma

HD201 is a mAb biosimilar to Roche's Herceptin which is used to treat patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Prestige's HD201 is in phase-III clinical development for filing with European Medicines Agency (EMA) and United States Food and Drug Administration (USFDA) in 2019.

Further product details are provided in the report.

Trastuzumab: Therapeutic Assessment

This segment of the report provides insights about the different Trastuzumab biosimilars segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Trastuzumab

There are approx. 35+ key companies which are developing the therapies for Trastuzumab.

  • Phases

DelveInsight's report covers around 35+ products under different phases of clinical development like

  • Marketed stage products
  • Late stage products (BLA Filed and Phase III)
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Trastuzumab pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Parenteral
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal antibodies
  • Peptide
  • Protein
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Trastuzumab: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Trastuzumab biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Trastuzumab biosimilar drugs.

Report Highlights:

  • The companies and academics are working to assess challenges and seek opportunities that could influence Trastuzumab R&D. The therapies under development are focused on novel approaches to treat/improve Trastuzumab.
  • In June 2019, Amgen and Allergan announced that the U.S. Food and Drug Administration (FDA) has approved Kanjinti (trastuzumab-anns) for all approved indications of the reference product, Herceptin (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Trastuzumab Biosimilars Report Insights

  • Trastuzumab Biosimilar Pipeline Analysis
  • Therapeutic Assessment
  • Sales Assessment
  • Unmet Needs
  • Impact of Drugs

Trastuzumab Biosimilar Report Assessment

  • Marketed Product profiles
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Sales Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Trastuzumab Biosimilars?
  • How many Trastuzumab biosimilars are developed by each company?
  • How many emerging biosimilars are in mid-stage, and late-stage?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Trastuzumab biosimilars therapeutics?
  • What are the clinical studies going on for Trastuzumab biosimilars and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Sunshine Guojian Pharmaceutical
  • STC Biologics
  • Shanghai Institute of Biological Products
  • Samsung Bioepis
  • Protheragen
  • Prestige Biopharma
  • Outlook Therapeutics
  • Nichi-Iko Pharmaceutical
  • Aprogen
  • NeuClone
  • Serum Institute of India
  • Mycenax Biotech
  • Meiji Seika Pharma
  • Mabpharm
  • Mabion
  • Jiangsu Hengrui Medicine Co.
  • ISU Abxis
  • International Biotech Center Generium
  • HisunPharmaceuticals
  • Hetero Group
  • Glenmark Pharmaceuticals
  • Genentech
  • Gedeon Richter
  • EirGenix
  • Dr Reddy's Laboratories
  • DM Bio
  • BioXpress Therapeutics
  • BioSavita
  • Bionovis
  • BioIntegrator
  • BIOCND
  • Biocad
  • AryoGen Pharmed
  • Apobiologix
  • Alteogen
  • Shanghai Henlius Biotech

Key Products

  • Cipterbin
  • STC 101
  • SIBP 01
  • SB3
  • Pro-S06
  • HD 201
  • ONS-1050
  • NeuCeptin
  • DMB-3111
  • CMAB 809
  • MabionHER2
  • SHR-1309
  • ISU103
  • GNR-027
  • HS-022
  • HBP7
  • HBP8
  • HBP9
  • HBP10
  • GBR-200
  • Anti-erbB-2- monoclonal antibody
  • EG12014
  • Hervycta
  • DA-3111
  • BX-2318
  • Anti-HER2 mAb biosimilar
  • BI-MAB-03
  • GB 221
  • BCD-022
  • AryoTrust
  • ALT02
  • HLX02

Table of Contents

1. Key Insights

2. Trastuzumab Biosimilars: Snapshot

3. Executive Summary

  • 3.1. Overview
  • 3.2. The Basics of Biologics.
  • 3.3. Biosimilars are not the Same as Generic Drugs
  • 3.4. Economics of Biosimilars - the Promise of Lower Prices, but at What Cost?
  • 3.5. What Patients Need to Know About Biosimilars

4. Regulatory Outlook For Biosimilars

  • 4.1. North America
    • 4.1.1. US
    • 4.1.2. Canada
  • 4.2. Europe
  • 4.3. Asia Pacific
    • 4.3.1. China
    • 4.3.2. India
    • 4.3.3. Japan
    • 4.3.4. South Korea
    • 4.3.5. Australia
  • 4.4. Rest Of The World
    • 4.4.1. Brazil
    • 4.4.2. Mexico
    • 4.4.3. Argentina
    • 4.4.4. Saudi Arabia

More Countries would be added in the final report

5. Trastuzumab (Reference Product: Herceptin)

  • 5.1. Drug Profile
  • 5.2. Product Overview
  • 5.3. Regulatory Approvals and Launch
  • 5.4. Indications
  • 5.5. Mechanism of Action
  • 5.6. Dosage and Administration
  • 5.7. Dosage and Strengths
  • 5.8. Dose Modification
  • 5.9. Route of Synthesis
  • 5.10. Pharmacology
  • 5.11. Pharmacodynamics
  • 5.12. Pharmacokinetics
  • 5.13. Adverse Reactions
  • 5.14. Product Snapshot
  • 5.15. Development Milestones

6. Research and Development

  • 6.1. Clinical Trials Information
  • 6.2. Safety and Efficacy

7. Herceptin Biosimilar: Emerging Opportunities

8. Trastuzumab: Biosimilars Assessment

  • 8.1. Assessment by Product Type
  • 8.2. Assessment by Route of Administration
  • 8.3. Assessment by Molecule type
  • 8.4. Sales Assessment

9. Trastuzumab Biosimilars Profiles: By Company

    • 9.1.1. Amgen
      • 9.1.1.1. Kanjinti: Amgen
      • 9.1.1.1.1. Product Information
      • 9.1.1.1.2. Research and Development
      • 9.1.1.1.3. Other Development Activities
      • 9.1.1.1.4. General Description Table
    • 9.1.2. EirGenix
      • 9.1.2.1. EG12014: EirGenix
      • 9.1.2.1.1. Product Information
      • 9.1.2.1.2. Research and Development
      • 9.1.2.1.3. Other Development Activities
      • 9.1.2.1.4. General Description Table
    • 9.1.3. Celltrion
      • 9.1.3.1. Herzuma: Celltrion
      • 9.1.3.1.1. Product Information
      • 9.1.3.1.2. Research and Development
      • 9.1.3.1.3. Other Development Activities
      • 9.1.3.1.4. General Description Table
    • 9.1.4. Prestige BioPharma
      • 9.1.4.1. HD201: Prestige BioPharma
      • 9.1.4.1.1. Product Information
      • 9.1.4.1.2. Research and Development
      • 9.1.4.1.3. Other Development Activities
      • 9.1.4.1.4. General Description Table

More Companies and products would be added in the final report

10. Trastuzumab Biosimilars: Comparative Landscape: By Company

11. Trastuzumab Biosimilars: Competitive Landscape

    • 11.1.1. Overview
    • 11.1.2. Market Share Analysis
    • 11.1.3. Competitive Scenario
      • 11.1.3.1. Product Launches and approval
      • 11.1.3.2. Partnerships, Collaborations and Agreements
      • 11.1.3.3. Acquisitions
      • 11.1.3.4. Expansions
      • 11.1.3.5. Patent Expiration of Biologics

More information would be added in the final report

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix

  • 15.1. Research Methodology
    • 15.1.1. Coverage
    • 15.1.2. Secondary Research

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1 Total Products for Trastuzumab
  • Table 2 Late Stage Products
  • Table 3 Mid Stage Products
  • Table 4 Early Stage Products
  • Table 5 Pre-clinical & Discovery Stage Products
  • Table 6 Assessment by Product Type
  • Table 7 Assessment by Stage and Product Type
  • Table 8 Assessment by Route of Administration
  • Table 9 Assessment by Stage and Route of Administration
  • Table 10 Assessment by Molecule Type
  • Table 11 Assessment by Stage and Molecule Type
  • Table 12 Inactive Products

List of Figures

  • Figure 1 Total Products for Trastuzumab
  • Figure 2 Late Stage Products
  • Figure 3 Mid Stage Products
  • Figure 4 Early Stage Products
  • Figure 5 Preclinical and Discovery Stage Products
  • Figure 6 Assessment by Product Type
  • Figure 7 Assessment by Stage and Product Type
  • Figure 8 Assessment by Route of Administration
  • Figure 9 Assessment by Stage and Route of Administration
  • Figure 10 Assessment by Molecule Type
  • Figure 11 Assessment by Stage and Molecule Type
  • Figure 12 Inactive Products